Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) is a clinical-stage biotech company pioneering treatments for orphan retinal diseases through innovative platforms like molecular photoswitch technology and DHODH inhibitors. This page serves as the definitive source for official news and developments related to KIO-301 (vision restoration therapy) and KIO-104 (ocular inflammation treatment).
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones including orphan drug designations, and strategic partnerships advancing retinal disease therapies. Our curated collection features press releases on Phase 2 trial outcomes, manufacturing agreements, and peer-reviewed research collaborations.
Key content categories include updates on inherited retinal degeneration treatments, non-steroidal anti-inflammatory developments, and regulatory pathway advancements. All materials maintain strict compliance with financial disclosure standards while prioritizing accessibility for both professional and public audiences.
Bookmark this page for streamlined access to Kiora's latest scientific advancements and corporate announcements. Regularly updated content ensures you stay informed about critical developments in vision-restoring therapies and ocular inflammation management.
Kiora Pharmaceuticals (NASDAQ: KPRX) presented promising preclinical data for KIO-104, their novel DHODH inhibitor, at ARVO 2025. The study demonstrated significant reduction in scar formation for treating proliferative vitreoretinopathy (PVR), the leading complication following retinal detachment surgery.
Key findings from the rabbit model study showed: The high dose group (10 μg/eye) completely prevented scar formation in all subjects. The low dose group (1 μg/eye) showed reduced scar formation with only 9 retinal scars in 2 of 6 rabbits, with mean scar length of 43 ± 16 μm. The control group developed 20 retinal scars in 4 of 6 animals, with mean scar length of 110 ± 28 μm.
KIO-104 is currently in Phase 2 clinical trials for macular edema treatment in patients with diabetic retinopathy and posterior non-infectious uveitis.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO Brian M. Strem, Ph.D., will deliver a presentation updating investors on the company's pipeline developments.
The presentation will focus on two key clinical trials: the planned Phase 2 trials of KIO-104 for retinal inflammation treatment and KIO-301 for retinitis pigmentosa treatment. Investors can access the live presentation through Kiora's investor relations website (ir.kiorapharma.com), with replay available for 90 days on the events page.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported its 2024 financial results and pipeline updates for retinal disease treatments. The company secured approvals for two Phase 2 trials: KLARITY (KIO-104 for retinal inflammation) and ABACUS-2 (KIO-301 for retinitis pigmentosa), with data expected in 2026.
Financial highlights include $26.8 million in cash and investments, plus $0.9 million in receivables, providing runway into 2027. The company reported net income of $3.6 million for 2024, compared to a $12.5 million loss in 2023, primarily due to $16 million in collaboration revenue from Laboratoires Théa.
R&D expenses reached $7.8 million in 2024, offset by $2.9 million in reimbursements from Théa. G&A expenses were $5.5 million, expected to remain consistent in 2025.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced that their preclinical study abstract for KIO-104 in treating proliferative vitreoretinopathy (PVR) will be presented at the ARVO 2025 Annual Meeting in Salt Lake City. The study demonstrates KIO-104's potential as a therapeutic candidate for both preventing and treating PVR.
The presentation, titled 'KIO-104, a novel small molecule inhibitor of DHODH, effectively prevents proliferative vitreoretinopathy in a rabbit model,' will showcase research evaluating multiple dose levels' effectiveness in reducing scar formation and magnitude in a retinal detachment model. KIO-104 functions by suppressing T cell division and function, potentially offering a new approach to reducing inflammation that leads to scar formation.
Currently, there are no approved treatments for PVR, a condition characterized by scar formation and retinal detachment following eye surgery or trauma. KIO-104 is simultaneously undergoing Phase 2 clinical trials for macular edema treatment.
Kiora Pharmaceuticals (NASDAQ: KPRX) has secured a new composition-of-matter patent (US-12209073-B2) for a specific crystalline form of KIO-104, their novel non-steroidal anti-inflammatory compound. The patent extends protection until 2043 and covers a unique polymorph that offers enhanced molecular stability and solubility, important for optimizing drug manufacturing.
The company is preparing to launch the KLARITY study, a Phase 2 clinical trial in the first half of 2025, which will evaluate KIO-104 in up to 28 patients with macular edema. The compound, as a locally delivered small molecule DHODH inhibitor, aims to provide an alternative to steroids or systemic anti-inflammatory drugs for treating retinal inflammation.
Kiora Pharmaceuticals (NASDAQ: KPRX) has received regulatory approval to begin KLARITY, a Phase 2 clinical trial for KIO-104 in treating retinal macular edema. The trial will evaluate a locally delivered small molecule as an alternative to steroids or systemic anti-inflammatory drugs.
The multi-center, open-label study will include up to 28 patients and will be conducted in two parts: Part A (Dose Optimization) will assess safety and efficacy of three injections every two weeks in 8 subjects across two cohorts (3.5 μg and 10 μg doses), while Part B (Cohort Expansion) will investigate different dosing regimens at intervals of 2 or 4 weeks.
KIO-104 works by suppressing T cell numbers and function in the eye through DHODH inhibition, targeting inflammation-related vision conditions including diabetic retinopathy, non-infectious uveitis, retinal vein occlusion, and post pseudophakic cataract surgery.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q3 2024 financial results and pipeline updates. The company received approval for ABACUS-2, a Phase 2 study of KIO-301 for retinitis pigmentosa, and finalized the Phase 2 KLARITY trial design for KIO-104. Financial position remains strong with $29.0 million in cash and equivalents, plus $1.8 million in collaboration receivables from Théa partnership. Q3 net loss was $3.4 million, improved from $5.8 million in Q3 2023. R&D expenses were $2.2 million, offset by $0.9 million in Théa reimbursements. The company expects runway into 2027, beyond anticipated clinical trial readouts.
Kiora Pharmaceuticals (NASDAQ: KPRX) received regulatory approval to initiate ABACUS-2, a Phase 2 clinical trial for KIO-301 in retinitis pigmentosa patients. The trial will involve 36 patients across five Australian centers, with participants randomized 2:1 to receive KIO-301 or control. The study will evaluate two dosage levels (50 and 100 micrograms) administered intravitreally every 6 weeks. KIO-301 is a photoswitch molecule designed to restore vision by targeting retinal ganglion cells, potentially benefiting patients regardless of their specific gene mutation. The trial's primary endpoints include safety and tolerability, with efficacy measured through functional vision assessments.
FAQ
What is the current stock price of KIORA PHARMACEUTICALS (KPRX)?
What is the market cap of KIORA PHARMACEUTICALS (KPRX)?
